Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingInhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q filed August 14, 2026, and encouraged stockholders and other interested parties to review the filing for a more complete discussion of the Company’s progress.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateApnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
- CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeFDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome, Quoin's second RPD and a potential second Priority Review Voucher
- GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic PillarsNew whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
- Anitoa Systems, LLCAnitoa Announces Secure Cloud Connectivity for its Portable qPCR Instruments, Unlocking Advanced Biosurveillance and AI IntegrationAnitoa Systems, LLC., a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing hardware, today announced a major advancement in point-of-care molecular testing: the integration of comprehensive cloud...
- MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD LawThe case alleges Regeneron and its top executives made false and/or misleading statements to investors.
- Alebund PharmaceuticalsAlebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA NephropathyAlebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
- Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive DirectorLindus Therapeutics names Dr. Gillian Cannon, former Merck and Roivant commercial leader, to its board as a non-executive director.
- Collegium Pharmaceutical, Inc.Collegium to Participate in Upcoming Investor ConferencesCollegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceCalidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.